Certain A Shares of Shanghai Yizhong Pharmaceutical Co., Ltd. are subject to a Lock-Up Agreement Ending on 9-SEP-2022. These A Shares will be under lockup for 371 days starting from 3-SEP-2021 to 9-SEP-2022.

Details:
Shareholding Arrangement, Voluntary Lockout Commitment of Shares and Shareholding and Reduction of Commitment of Shareholders holding more than 5%.
The company's controlling shareholder and the Company's actual controller, Zhou Jinsong, and Shanghai Yixing Enterprise Management Partnership (Limited Partnership)?Shanghai Shanyuan Enterprise Management Partnership (Limited Partnership)committed that within 36 months since the date of listing of the present shares, there will not be no transfers nor entrustment of shares to any third party nor repurchase by the Company. After the expiry of the lock-up period (including the extended lock-up period), during the time serves as the company director, supervisor and senior manager, the party promise that yearly transfer of shares made by him/her will not exceed 25% of the holding.

Commitments of directors, supervisors, and senior executives who directly or indirectly hold the issuer's shares Li Duan, Sun Jing, Zhang Ligao, Pan Ruojun, Wu Bin, Meng Xinran, Chen Yaping, Fang Zhou, Liu Gang, Zhang Wenming, and Qiu Yi, the core technical personnel who directly or indirectly hold shares of the issuer that within 12 months since the date of listing of the present shares, there will not be no transfers nor entrustment of shares to any third party nor repurchase by the Company. If, within 6 months after the issuer's listing, the closing price of the shares is lower than issuance price for 20 consecutive trading days or if trading price is lower than issuance price after 6 month from listing, lock-up period will be automatically extended for another 6 months. After the expiry of the lock-up period (including the extended lock-up period), during the time serves as the company director, supervisor and senior manager, the party promise that yearly transfer of shares made by him/her will not exceed 25% of the holding.

All other shareholders Shanghai Kaibao Pharmaceutical CO., Ltd, Shanghai Xianyu Investment Center (Limited Partnership), Shanghai Jianxin Kangying Venture Capital Partnership (Limited Partnership), Jiangsu Yida Achievement Innovation Venture Capital Fund (Limited Partnership), Shengduo Jinji (Shanghai) Asset Management Co., Ltd., Shanghai Yixian Health Management Consulting Center (Limited Partnership), Zeng Meihua, Li Feng, Li Xun, Xu Yuexiang, Shen Yaling, Zhao Yusheng, Jiang Yongmei, Qian Zhiping, Wang Xuemei, Chen Jiwan, Liu Bin, Jiang Xinguo, Feng Yanbin, Liao Chaojian's promise commit that within 12 months since the date of listing of the present shares, there will not be no transfers nor entrustment of shares to any third party nor repurchase by the Company.